NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare NeurAxis to related businesses based on the strength of its profitability, institutional ownership, valuation, analyst recommendations, risk, dividends and earnings.
Institutional & Insider Ownership
11.8% of NeurAxis shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares NeurAxis and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeurAxis | -492.76% | N/A | -641.25% |
| NeurAxis Competitors | -191.42% | -197.84% | -21.82% |
Valuation & Earnings
This table compares NeurAxis and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| NeurAxis | $6.53 million | -$14.63 million | -4.25 |
| NeurAxis Competitors | $1.90 billion | $138.28 million | 5.83 |
NeurAxis’ peers have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
NeurAxis has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, NeurAxis’ peers have a beta of 2.58, indicating that their average stock price is 158% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for NeurAxis and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeurAxis | 0 | 1 | 1 | 0 | 2.50 |
| NeurAxis Competitors | 4323 | 10550 | 18353 | 839 | 2.46 |
NeurAxis currently has a consensus price target of $13.00, indicating a potential upside of 188.89%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 27.49%. Given NeurAxis’ stronger consensus rating and higher probable upside, equities research analysts clearly believe NeurAxis is more favorable than its peers.
Summary
NeurAxis peers beat NeurAxis on 9 of the 13 factors compared.
NeurAxis Company Profile
NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
